The McGill Regenerative Network has a horizontal configuration and its administrative structure is streamlined for simplicity and rapid responses to opportunities.

The directorship is held for 4 years, named by the Faculty of Medicine and the Vice-Principal Research-Innovation. The Director is assisted by a Coordinator and its mandate is approved by the MRM Executive Committee composed of researchers from across all departments.

The MRM Network has 7 key committees dedicated to advancing each of the five commitments for its overall strategy.

 

Administration

Professor Michel L. Tremblay

Director
        
Learn more

Professor Michel L. Tremblay

Director

Dr. Michel L. Tremblay, Ph.D. is a James McGill Professor and former director of the Goodman Cancer Research Centre His laboratory works on characterizing the function and regulation of several members of the Protein Tyrosine Phosphatase (PTP) gene family using both biochemical and genetic approaches. Dr. Tremblay’s lab is also developing several new approaches towards PTP inhibition, as well as large siRNA gene family screens in order to uncover potential applications of these in various diseases (diabetes, obesity, spinal cord injury, neural degenerative diseases, intestinal bowel diseases and other inflammatory diseases), particularly in human cancers.

Dr. Marine Christin

Coordinator
        
Learn more

Dr. Marine Christin

Coordinator

Contact:

Email: mrm.coordinator@mcgill.ca

Phone: 514-398-7595

Executive Committee

Dr. Inés Colmegna

Division of Rheumatology, RI-MUHC
        
Learn more

Dr. Inés Colmegna

Division of Rheumatology, RI-MUHC

My lab research focuses on defining basic mechanisms involved in the disruption of immune tolerance in patients with rheumatoid arthritis (RA). We are specifically interested in understanding the role that adult stem cells have in initiating and perpetuating this disease. Ongoing studies aim to characterize the biology of human hematopoietic and mesenchymal stem cells in patients with recent onset and established RA, the cross talk between stem cells and other immune cells, and the impact that interventions targeting stem cells have on the restoration of immune function.

Dr. Colin Crist

Human Genetics, Lady Davis Institute
        
Learn more

Dr. Colin Crist

Human Genetics, Lady Davis Institute

Dr. Crist’s laboratory at the Lady Davis Institute for Medical Research investigates the molecular biology underlying skeletal muscle development and regeneration. Deepening our understanding of how muscle stem cells develop and function will be key to realizing regenerative medicine based approaches to treating muscle disorders.

Dr. Thomas Durcan

Neurology and Neurosurgery, Montreal Neurological Institute
        
Learn more

Dr. Thomas Durcan

Neurology and Neurosurgery, Montreal Neurological Institute

As an assistant professor at the Montreal Neurological Institute (MNI) and McGill University, my research focus is on applying patient-derived stem cells towards the development of phenotypic discovery assays and 3D mini-brain models for both neurodegenerative and neurodevelopmental disorders. As group leader of the iPSC platform at the Montreal Neurological Institute (MNI), I oversee a team of 30 research staff and students and growing, committed to applying novel stem cell technology, combined with CRISPR genome editing, mini-brain models and new microfluidic technologies towards elucidating the underlying causes of these complex disorders. Leading the SGC tissue platform, NeuroSGC; I oversee a team committed to assay development, in parallel with leading the establishment of NeuroCDRD, towards the automation of our open assays for small molecule screens. In addition, I am also part of antibody validation efforts between the MNI, Oxford and the Karolinska to generate CRISPR KO cell-lines for validating commercial antibodies against high-value ALS targets. Combined with new approaches in the group towards building multiomic profiles on the patient-derived IPSC cells within the group, the long-term strategy over the coming years is to identify new personalized precision therapies that can be applied towards building clinical trials on a dish.

Dr. Carl Ernst

Psychiatry, Douglas Research Center
        
Learn more

Dr. Carl Ernst

Psychiatry, Douglas Research Center

Carl Ernst, is currently a professor at McGill in the departments of Human Genetics, Neuroscience, and Psychology. The goal of his work is to study human behaviour and mood by identifying genes that may be involved in mental disorders. For this work, he produces cellular models based on the functions of specific genes, and screens at-risk populations for genetic mutations, deriving stem cells from their tissues. He then assesses how neurons derived from these subjects’ stem cells differ from neurons derived from healthy patients.

Dr. Alex Gregorieff

Pathology, RI-MUHC
        
Learn more

Dr. Alex Gregorieff

Pathology, RI-MUHC

One of the extraordinary abilities of all living creatures is their capacity to repair damaged tissues following injury. This regenerative property is in large part due to the existence of stem cells that are defined by their ability to replace themselves through division, as well as giving rise to specialized cell types through a process known as differentiation. Unfortunately, once stem cells acquire mutations that cause them to proliferate incessantly, they can also fuel cancer growth. My lab focuses on the stem cells in the epithelial lining of our intestinal tract. By constantly replenishing the gut epithelium, intestinal stem cells ensure proper nutrient uptake and barrier formation against environmental toxins and pathogens throughout life. My interests lie in understanding the signals that control gut stem cell behaviour and how these signals become misregulated in diseases such as inflammatory bowel disease and colon cancer.

Professor Terry Hébert

Pharmacology and Therapeutics
        
Learn more

Professor Terry Hébert

Pharmacology and Therapeutics

Terry Hébert’s research focus is on the ontogeny, formation and trafficking of GPCR-based signalling complexes with a view toward understanding the architecture, wiring and integration of individual GPCR signalling pathways both at the cell surface and in the nucleus. Our primary focus is in the context of cardiovascular disease. He has developed new methods for in cellulo measures of protein/protein interactions and is highly involved in the development of new multiplexed signalling assays for drug discovery. The lab is now poised to exploit patient-derived iSPC lines to develop personalized understanding of disease and its treatment.

Dr. Corinne Hoesli

Chemical Engineering
        
Learn more

Dr. Corinne Hoesli

Chemical Engineering

The Stem Cell Bioprocessing Laboratory works on engineering bioreactors for stem cell culture. We apply engineering approaches to design, optimize and scale up stem cell production systems. We are currently investigating the effects of various biomaterials and 3D culture on pluripotent stem cell differentiation into pancreatic cells as well as vascular endothelial cells. The main areas of applications of our research are diabetes cellular therapy and the development of vascular substitutes to treat cardiovascular disease.

Me Erika Kleiderman

Human Genetics, Centre of Genomics and Policy
        
Learn more

Me Erika Kleiderman

Human Genetics, Centre of Genomics and Policy

Erika Kleiderman is a lawyer and an Academic Associate at the Centre of Genomics and Policy at McGill University. Her research deals with the ethical, legal, and social implications surrounding access to data and genetic information, biobanking, and the regulation of stem cells, regenerative medicine, and new reproductive technologies. Erika is involved with the Stem Cell Network’s Trainee Communications and Training & Education Committees, as well as the coordinator of the pan-Canadian initiative aimed at assessing the adequacy of existing regulatory frameworks and considerations for reframing the Assisted Human Reproduction Act, in light of evolving reproductive technologies. She is also the Coordinator of the Canadian International Data Sharing Initiative (Can-SHARE) and the Access Officer of the Canadian Partnership for Tomorrow Project (CPTP). Erika’s interests expand to the potential implications of gene therapy / enhancement in minors within a sporting context.

Committees

Dr. Natasha Chang

Chair of the Scientific Programming Committee
        
Learn more

Dr. Natasha Chang

Chair of the Scientific Programming Committee

Dr. Natasha Chang received her Ph.D. in Biochemistry from McGill University, and pursued her postdoctoral fellowship at the Ottawa Hospital Research Institute. Dr. Chang joined McGill as an Assistant Professor in the Department of Biochemistry in 2019. Research in the Chang laboratory focuses on understanding the molecular signalling mechanisms that regulate muscle stem cell function and how these pathways are altered in the context of muscle degenerative disease and muscle cancer. The ultimate goal for Dr. Chang’s research team is to identify molecular targets to improve endogenous stem cell regenerative capacity as well as strategies to improve stem cell transplantation therapy.

Dr. Colin Crist

Chair of the Web & Communication Committee
        
Learn more

Dr. Colin Crist

Chair of the Web & Communication Committee

Dr. Crist’s laboratory at the Lady Davis Institute for Medical Research investigates the molecular biology underlying skeletal muscle development and regeneration. Deepening our understanding of how muscle stem cells develop and function will be key to realizing regenerative medicine based approaches to treating muscle disorders.

Professor Terry Hébert

Chair of the Education Committee
        
Learn more

Professor Terry Hébert

Chair of the Education Committee

Terry Hébert’s research focus is on the ontogeny, formation and trafficking of GPCR-based signalling complexes with a view toward understanding the architecture, wiring and integration of individual GPCR signalling pathways both at the cell surface and in the nucleus. Our primary focus is in the context of cardiovascular disease. He has developed new methods for in cellulo measures of protein/protein interactions and is highly involved in the development of new multiplexed signalling assays for drug discovery. The lab is now poised to exploit patient-derived iSPC lines to develop personalized understanding of disease and its treatment.

Me Erika Kleiderman

Chair of the Ethics Committee
        
Learn more

Me Erika Kleiderman

Chair of the Ethics Committee

Erika Kleiderman is a lawyer and an Academic Associate at the Centre of Genomics and Policy at McGill University. Her research deals with the ethical, legal, and social implications surrounding access to data and genetic information, biobanking, and the regulation of stem cells, regenerative medicine, and new reproductive technologies. Erika is involved with the Stem Cell Network’s Trainee Communications and Training & Education Committees, as well as the coordinator of the pan-Canadian initiative aimed at assessing the adequacy of existing regulatory frameworks and considerations for reframing the Assisted Human Reproduction Act, in light of evolving reproductive technologies. She is also the Coordinator of the Canadian International Data Sharing Initiative (Can-SHARE) and the Access Officer of the Canadian Partnership for Tomorrow Project (CPTP). Erika’s interests expand to the potential implications of gene therapy / enhancement in minors within a sporting context.

Dr. Vahab Soleimani

Chair of the Prizes & Awards Committee
        
Learn more

Dr. Vahab Soleimani

Chair of the Prizes & Awards Committee

My research program is focused on uncovering the epigenetic and transcriptional machinery that regulates stem cell self-renewal and differentiation using skeletal muscle regeneration as a model. Loss of stem cell or their diminished function underlies numerous muscle-wasting diseases. We are interested in identifying relevant molecular pathways that can be targeted by specific drugs to boost muscle stem cell self-renewal and expansion as a therapeutic strategy to treat muscle wasting-diseases.

Professor Michel L. Tremblay

Chair of the Funding and Infrastructures Committee
        
Learn more

Professor Michel L. Tremblay

Chair of the Funding and Infrastructures Committee

Dr. Michel L. Tremblay, Ph.D. is a James McGill Professor and former director of the Goodman Cancer Research Centre His laboratory works on characterizing the function and regulation of several members of the Protein Tyrosine Phosphatase (PTP) gene family using both biochemical and genetic approaches. Dr. Tremblay’s lab is also developing several new approaches towards PTP inhibition, as well as large siRNA gene family screens in order to uncover potential applications of these in various diseases (diabetes, obesity, spinal cord injury, neural degenerative diseases, intestinal bowel diseases and other inflammatory diseases), particularly in human cancers.

Copyright © 2019 McGill Regenerative Medicine Network. All rights reserved. Website by KORSR Studio, Valérie Provost & ER5.